ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.480,89
0,21%
S&P 500
5.187,67
0,00%
US Dollar vs BRL
5,0891
-0,01%
Bitcoin
61.596,28
0,67%
Brent Oil
83,68
0,14%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Eton Pharmaceuticals Inc (ETON)

  7. Eton Pharmaceuticals Inc (ETON) Notícias

ETON

Eton Pharmaceuticals (ETON)

Eton Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ETON
DataHoraFonteTítuloCódigoCompanhia
01/05/202417:05GlobeNewswire Inc.Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ETONEton Pharmaceuticals Inc
30/04/202408:00GlobeNewswire Inc.Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)NASDAQ:ETONEton Pharmaceuticals Inc
29/04/202417:30GlobeNewswire Inc.Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:ETONEton Pharmaceuticals Inc
22/03/202403:00GlobeNewswire Inc.Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaNASDAQ:ETONEton Pharmaceuticals Inc
14/03/202417:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
29/02/202418:01GlobeNewswire Inc.Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024NASDAQ:ETONEton Pharmaceuticals Inc
21/02/202408:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ETONEton Pharmaceuticals Inc
21/02/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid FormulationNASDAQ:ETONEton Pharmaceuticals Inc
15/02/202418:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ETONEton Pharmaceuticals Inc
02/02/202408:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone CapsulesNASDAQ:ETONEton Pharmaceuticals Inc
09/11/202318:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ETONEton Pharmaceuticals Inc
09/11/202318:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
30/10/202307:50GlobeNewswire Inc.Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023NASDAQ:ETONEton Pharmaceuticals Inc
18/10/202309:00PR Newswire (US)SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdateNASDAQ:ETONEton Pharmaceuticals Inc
04/10/202307:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product NitisinoneNASDAQ:ETONEton Pharmaceuticals Inc
23/08/202307:50GlobeNewswire Inc.Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ETONEton Pharmaceuticals Inc
10/08/202317:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Second Quarter 2023 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
01/08/202317:05GlobeNewswire Inc.Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023NASDAQ:ETONEton Pharmaceuticals Inc
28/06/202308:42Dow Jones NewsEton Pharma Gets FDA Complete Response Letter for Dehydrated Alcohol InjectionNASDAQ:ETONEton Pharmaceuticals Inc
28/06/202307:56Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ETONEton Pharmaceuticals Inc
28/06/202307:50GlobeNewswire Inc.Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol InjectionNASDAQ:ETONEton Pharmaceuticals Inc
11/05/202317:21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ETONEton Pharmaceuticals Inc
11/05/202317:01GlobeNewswire Inc.Eton Pharmaceuticals Reports First Quarter 2023 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
10/05/202307:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)NASDAQ:ETONEton Pharmaceuticals Inc
03/05/202317:05GlobeNewswire Inc.Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023NASDAQ:ETONEton Pharmaceuticals Inc
27/04/202317:34Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ETONEton Pharmaceuticals Inc
21/03/202307:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ETONEton Pharmaceuticals Inc
16/03/202317:01GlobeNewswire Inc.Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial ResultsNASDAQ:ETONEton Pharmaceuticals Inc
15/03/202307:50GlobeNewswire Inc.Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600NASDAQ:ETONEton Pharmaceuticals Inc
07/03/202318:05GlobeNewswire Inc.Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023NASDAQ:ETONEton Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ETON

Seu Histórico Recente

BOV
COGN3
COGNA ON
BOV
IBOV
Índice Bovespa
BOV
JHSF3
JHSF PART ON
BOV
OIBR3
OI ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
VVEO3
CM Hospitalar ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
SGPS3
SPRINGS ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
BRKM5
BRASKEM PNA
BOV
ENAT3
ENAUTA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados